§ 24-2A-2. Definitions

As used in the Theodore R. Montoya Memorial Hemophilia Program Act: A. “blood products” means certain components or factors obtained from whole blood which when periodically administered to persons suffering from hemophilia result in relief or control of the disease; B. “eligible patient” means a person suffering from hemophilia whose case has been evaluated and accepted for provision of services by the hemophilia program established by the school; C. “fund” means the hemophilia fund; D. “hemophilia” means a genetic disease in which uncontrolled bleeding from otherwise minor causes may result in death or disability; E. “hemophilia program” means the New Mexico comprehensive hemophilia diagnostic and treatment program established by the school to provide comprehensive clinical evaluation of patients suffering from hemophilia, out-patient blood product usage, counseling services to families of persons suffering from hemophilia and outreach to the public; F. “provider” means any blood service or laboratory furnishing blood products to the school and its program administration for eligible patients; G. “university” means the university of New Mexico; and H. “secretary” means the secretary of health and environment [secretary of health].